Skip to main content
Start triage

Start triage first, then route to emergency care.

Need urgent help? Start triage first, then route to emergency care.

Roxee Medication Guide

Desoxycorticosterone Pivalate

Medication reference facts with explicit FDA-approval, off-label, source-limited, and safety context. Roxee does not sell, prescribe, or dispense medications.

Both Reference complete FDA data linked Rx required Liquid (Suspension) Multiple FDA labelers Official label facts Owner quick guide first

Veterinary professional?

Showing simplified owner view. Switch to Vet View for full technical detail.

Data freshness

Reference facts
Reference refreshed
Jun 22, 2026, 10:41 a.m.

These are the reference facts Roxee uses on browse cards and quick facts.

FDA applications
FDA application data refreshed
Jun 22, 2026, 10:41 a.m.

Sponsor, product, and application records imported from Animal Drugs @ FDA.

Safety reports
Safety data refreshed
Apr 26, 2026, 10:02 a.m.

openFDA reaction terms and case summaries are supporting evidence, not proof of causality.

Source timing details
Source timing details
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Image coming soon
Desoxycorticosterone Pivalate

Desoxycorticosterone Pivalate

Drug type: Generic ingredient • Branded profile FDA branded products available

Both Liquid (Suspension) Rx required 100% reference complete

Species: Both

Manufacturer: Multiple FDA labelers

Medication Snapshot

Merged from the current Roxee medication system with field-level provenance, freshness, and completeness tracking.

Desoxycorticosterone Pivalate

For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency. For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison’s disease). Species commonly shown: Both, Dog, Restricted During Pregnancy, Dog.

Generic name
Desoxycorticosterone Pivalate
Brand names
Percorten™-V, Zycortal® Suspension, Desoxycorticosterone Pivalate, ZYCORTAL
Manufacturer
Multiple FDA labelers
Species
Both, Dog
Dosage forms
Liquid (Suspension), Injectable Suspension
Prescription
Prescription required
Completeness
100%
Validation
Complete
Brand names
Percorten™-V Zycortal® Suspension Desoxycorticosterone Pivalate ZYCORTAL
Dosage forms
Liquid (Suspension) Injectable Suspension

Indications / Uses

For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency. For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison’s disease).

Warnings / Contraindications

For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Side Effects

Top reported reactions (openFDA): Immediate pain upon injection, High sodium-potassium ratio (Na:K ratio), Lethargy (see also Central nervous system depression in 'Neurological'), Vomiting, Polyuria, Polydipsia.

FAQ

Both, Dog, Restricted During Pregnancy, Dog

Yes. Roxee shows this as prescription-only.

Liquid (Suspension), Injectable Suspension

Source Transparency

Add to My Pet's Medications

Choose a pet, confirm current or past, and optionally add reminder notes.

Sign in to save this medication to your pet profile.

Sign in to continue

Pet Owner Quick Guide

Start here first for the safest next-step summary before the deeper medication detail.

Used for:

For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.

Dosing note:

Exact dosing depends on your pet's species, weight, and health status. Use your veterinarian's instructions for the exact dose and schedule.

What to watch for:

  • For intramuscular use only
  • Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema
  • For subcutaneous use in dogs only
  • wobbly/unsteady walking (1 reports)
  • Lymphopenia (1 reports)
  • Loss of appetite (1 reports)

When to call the vet:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.
  • Facial swelling or hives.
  • Blood in vomit or stool.

Regulatory restrictions are shown in Vet View.

What to tell or ask your vet today:

  • Is this medicine the right fit for my pet’s current symptoms?
  • Which warning signs mean I should call back right away?
  • How should I handle missed doses or refusal to take the medicine?

Next actions

Research brief

Medication Research Insights

A source-aware map of what to know, what is uncertain, and what to verify with your veterinarian.

Source Backed Signals

What to know

Evidence-backed context Limited

Roxee has limited cited overview evidence for Desoxycorticosterone Pivalate; use the official documents and your veterinarian's instructions for product-specific decisions.

Source: openFDA case USA-USFDACVM-2021-US-000678
Safety signal coverage Reported signals

32 tracked reaction signals; 32 reported cases; 27 serious reports; 2 species groups. These are reporting and label-derived signals for interpretation with a veterinarian.

Source: openFDA case USA-USFDACVM-2021-US-000678
Interpretation guardrail Not causation

Adverse-event reports help form a watch list, but they do not prove the medication caused the reaction and they are not a risk ranking between medications.

Evidence tension

Stronger signal Label / review

Official labels, package inserts, and reviewed summaries carry more weight than isolated reports.

Source: openFDA case USA-USFDACVM-2021-US-000678
Weaker signal Reported data

Case reports and openFDA terms are useful for pattern awareness, but they are incomplete, can include multiple exposures, and do not estimate an individual pet's probability of harm.

Reaction signal map

Most reported reactions Top terms

Unsteady walking (ataxia) (1 reports), Lymphopenia (1 reports), Loss of appetite (1 reports), Localised oedema (1 reports), Leucocytosis NOS (1 reports)

Body systems represented Signal grouping

Digestive (2), Skin & allergy (1), Neurologic (1), Effectiveness (2)

Explore supporting adverse reports

Species and breed lens

Species represented in reports Species lens

Cat (17 reports), Dog (15 reports)

Breed metadata in reports Metadata only

Shepherd Dog - Australian (1), ['Chihuahua', 'Dog (unknown)'] (1). These are report metadata, not proof that a breed is at higher risk.

What your vet may verify

Fit for this patient Vet check

Verify whether Desoxycorticosterone Pivalate fits the pet's species, current diagnosis, age, weight, organ status, pregnancy/lactation status, and concurrent medications.

Evidence limitations Evidence review

Separate label-backed warnings from adverse-event reports and owner observations before changing the plan.

What to watch next

Watch list Owner-safe

For intramuscular use only, Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or, For subcutaneous use in dogs only, wobbly/unsteady walking, Lymphopenia

Call sooner if Escalation

Repeated vomiting or diarrhea. Severe lethargy (hard to wake, very low energy). Collapse or fainting.

Bottom line: Use this Desoxycorticosterone Pivalate brief as a structured watch list and source map, not as a reason to start, stop, or change treatment without your veterinarian.
Vet source depth
  1. openFDA case USA-USFDACVM-2021-US-000678 · adverse_reaction · adverse reactions
  2. Contraindication source · fda_animal_drugs · warnings contraindications
  3. FDA application profile · official_label · quick facts
  4. FDA application profile · official_label · quick facts
  5. Medication usage source · fda_animal_drugs · quick facts
  6. FOI · document · documents
  7. SPL · document · documents
  8. FOI · document · documents

Evidence

Review status / Updated / Sources

Review status: Clinical reviewer not listed

Updated: February 12, 2026, 10:44 PM UTC

Sources:
Safety & side effects

Side effects to monitor:

  • For intramuscular use only
  • Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema
  • For subcutaneous use in dogs only
  • wobbly/unsteady walking
  • Lymphopenia

Most reported reactions:

  • Unsteady walking (ataxia) (1 reports)
  • Lymphopenia (1 reports)
  • Loss of appetite (1 reports)
Explore reported case details

Emergency warning signs:

  • Repeated vomiting or diarrhea.
  • Severe lethargy (hard to wake, very low energy).
  • Collapse or fainting.
  • Trouble breathing.

Vet Fast Scan

Source-backed clinical checkpoints for quick review.

FDA-labeled species
Dog
Indication / use
For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.
Form / route / dose
Form: Injectable Suspension, Liquid (Suspension)
Route: Intramuscular, Subcutaneous
Confirm product label and patient-specific plan.
Warnings
  • High: For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal dis…
Adverse-event caveat
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.

Quick Facts

Official label facts first, then secondary summaries. Marketing content is separated below.

Species: Both
Manufacturer: Multiple FDA labelers
Form: Injectable Suspension, Liquid (Suspension)
Identifiers:
NADA: 141029 NADA: 141444 NDC Package: 17033-382-04 NDC Package: 58198-6450-0 NDC Product: 17033 NDC Product: 58198
Source metadata:

Warnings / Contraindications

For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

  • High: For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.
Source metadata:

Adverse Reactions

Snapshot first, detailed rows second. This section summarizes signal data and is not a diagnosis.

Reported case explorer

Filter stored openFDA reports by pet and report attributes. Counts describe reports in this data set, not risk.

Clear filters
openFDA adverse-event cases are reported signals. They are not verified, do not prove causation, and do not estimate a pet's individual risk.
Stored reports
2
Matching reports
1
Active filters
1
Selected filters
Reaction: Dry mucous membrane Clear
Reset
Showing up to 50 matching reports.

USA-USFDACVM-2025-US-064279

Received 2025-10-28 · MSK · MSK

Serious
Species
Dog
Breed
Shepherd Dog - Australian
Size / weight
10-24 lb (6.804 Kilogram)
Age
8+ years (15 Year)
Sex
Male Neutered
Region
USA
Reactions
AtaxiaUnable to walkPale mucous membraneDry mucous membraneLaboured breathingPericardial effusionLeucocytosis NOS
Body systems
NeurologicOther
Outcomes
Ongoing

Tap or hover a reaction to see what it means in plain language.

Tracked signals
32
Reported cases
32
Serious reports
27
Species represented
2
Grouped by Body System
Digestive (2) · Loss of appetite, Decreased appetite Skin & allergy (1) · Itching Neurologic (1) · Unsteady walking (ataxia) Effectiveness (2) · Lack of efficacy - NOS, Lack of efficacy (endoparasite) - whipworm Other (26) · Lymphopenia, Localised oedema, Leucocytosis NOS
Most Reported Reactions
Reaction Body system Cases Species Serious cases
Neurologic 1 Dog 1
Other 1 Cat 1
Digestive 1 Cat 1
Other 1 Dog 1
Other 1 Dog 1
Effectiveness 1 Dog 1
Other 1 Dog 1
Other 1 Cat 1

Species coverage: Cat (17) Dog (15)

View detailed reaction table
Reaction Body system Species Seriousness Frequency Reports
Neurologic Dog Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Effectiveness Cat Non-serious - 1
Effectiveness Dog Serious - 1
Other Dog Serious - 1
Skin & allergy Dog Non-serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Dog Non-serious - 1
Other Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Other Cat Serious - 1
Digestive Cat Serious - 1
Other Dog Serious - 1
Other Dog Serious - 1
Other Cat Serious - 1
Source metadata:

Source Documents

The most useful source links appear first; full previews and metadata stay in the veterinary/professional layer.

Use original documents to confirm product-specific warnings, ingredients, and handling details with your veterinarian.

Full source previews and metadata remain in the veterinary/professional layer.

Owner handouts

0
No owner handouts linked yet.

Official label / PI

0
No official label or package insert links yet.

SPL

4

FOI

2

Percorten™-V

SPL · SPL

FDA Structured Product Label

Percorten™-V

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Elanco US Inc.
NADA
141-029
Status
RX
Form
Liquid (Suspension)
Route
Intramuscular
Species
Dog
Composition / specifications
Each milliliter of sterile aqueous suspension contains 25 milligrams of desoxycorticosterone pivalate.

Dogs

Indication
For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.
Dosage
Dosage requirements are variable and must be individualized on the basis of the response of the patient to therapy. Initial dose of 1 milligram per pound (0.45 kilogram) of body weight every 25 days, intramuscularly. Usual dose is 0.75 to 1.0 milligram per pound of body weight every 21 to 30 days.
Limitations
For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Zycortal® Suspension

SPL · SPL

FDA Structured Product Label

Zycortal® Suspension

Rendered from Roxee's cached FDA SPL package contents for on-page reading. Use Open original for the raw FDA ZIP/XML source.

Sponsor
Dechra, Ltd.
NADA
141-444
Status
RX
Form
Injectable Suspension
Route
Subcutaneous
Species
Dog
Composition / specifications
25 mg/mL

Dogs

Indication
For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison’s disease).
Dosage
Administer an initial dose of 2.2 mg/kilogram (1 mg/lb) body weight by subcutaneous injection. Subsequent dosages should be individualized according to label instructions based on patient response to therapy.
Limitations
For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Desoxycorticosterone Pivalate SPL

SPL · Structured Product Label

FDA Structured Product Label XML for Desoxycorticosterone Pivalate. Use the source link for the full official labeling record.

ZYCORTAL SPL

SPL · Structured Product Label

FDA Structured Product Label XML for ZYCORTAL. Use the source link for the full official labeling record.

N141029 Org_1_12_1998.pdf

FOI · FOI

UCM488818.pdf

FOI · FOI

Veterinary reference (advanced)

Canonical medication sections are above. This legacy block remains available for deeper cross-reference without cluttering the primary workflow.

At a Glance

Quick facts and links to official labeling and safety signals.

Data freshness
  • Reference facts: Source Roxee | Refreshed Jun 22, 2026, 10:41 AM UTC
    The reference fact projection used for browse cards and quick facts.
  • Animal Drugs @ FDA: Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Applications/products are imported from FDA export data.
  • Animal Drugs @ FDA previews: Source FDA | Refreshed Feb 9, 2026, 3:05 AM UTC
    Label highlights/doc links are fetched from FDA preview endpoints.
  • Animal Drug Product Listing Directory (NDC): Source FDA | Refreshed Jun 22, 2026, 10:41 AM UTC
    Package/product NDCs from FDA’s electronic listing directory (XLS).
  • openFDA reaction terms: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
  • openFDA case summaries: Source FDA openFDA | Refreshed Jun 22, 2026, 10:45 AM UTC
Official (FDA)
Identity: Generic ingredient • FDA branded products available
Official FDA brands: Desoxycorticosterone Pivalate ZYCORTAL
Manufacturer mapping: Multiple FDA labelers
Case-reported brands (openFDA): MSK
Catalog species: Both FDA-labeled species: Dog
Rx/OTC: RX
Form/route: Injectable Suspension, Liquid (Suspension) Intramuscular, Subcutaneous
Applications: NADA 141-029 • NADA 141-444
NDC: Packages 17033-382-04 58198-6450-0 Products 17033 58198
Documents: 2 (FOI: 2) • SPL: 2 Label highlights Official documents
Safety (openFDA)
Top reactions: Dog 12 Cat 0 View
Case summaries: 2 (showing 2) View
openFDA reports are unverified and do not prove causation.

Explore
Linked using: Fda_Label (0.95), Fda_Label (0.95)

Diagnosis Codes
ICD10_CM: E27.1
Primary adrenocortical insufficiency

Counseling and Monitoring Highlights

Global Pet owner/Vet mode is controlled in the header. This section avoids duplicate in-page persona tabs.

Owner-facing counseling points
  • For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian. (Contraindication, High)
Top reaction signals
Unsteady walking (ataxia) (1) Lymphopenia (1) Loss of appetite (1) Localised oedema (1) Leucocytosis NOS (1) Lack of efficacy (endoparasite) - whipworm (1) Laboured breathing (1) Increased red blood cell count (1)

Identifiers & Packages

Normalized identifiers (NDC/NADA/ANADA) and package metadata from regulator listings.

Identifiers
NADA: 141029 NADA: 141444 NDC Package: 17033-382-04 NDC Package: 58198-6450-0 NDC Product: 17033 NDC Product: 58198
Package NDC Product NDC Form / Route Status
17033-382-04 17033 -
58198-6450-0 58198 -

Enriched Documents

Documents are tiered by source trust: Official, Clinical, Manufacturer, Marketing.

  • Desoxycorticosterone Pivalate SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • ZYCORTAL SPL • Structured Product Label • Official
    FDA Structured Product Label from the electronic animal drug product listing directory.
  • N141029 Org_1_12_1998.pdf • FOI summary • Official • June 18, 2018
    FDA FOI summary for application 141029
  • UCM488818.pdf • FOI summary • Official • June 1, 2016
    FDA FOI summary for application 141444

Data Sources & Change Log

Every non-trivial field is expected to include provenance and update timestamps.

Official 123 Clinical 1 Manufacturer 0 Marketing 0
Current Field Facts
  • side_effects: Top reported reactions (openFDA): Immediate pain upon injection, High sodium-potassium ratio (Na:K ratio), Lethargy (see also Central nervous system depression… (Clinical, 2026-04-11)
  • contraindications: For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts th… (Official, 2026-04-12)
  • contraindications: For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts th… (Official, 2026-04-11)
  • contraindications: For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts th… (Official, 2026-02-12)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-22)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-22)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-21)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-20)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-13)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-12)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-12)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-11)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-11)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-10)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-09)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-08)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-07)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-06)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-05)
  • manufacturer_name: Multiple FDA labelers (Official, 2026-06-04)
Recent Revisions
  • side_effects updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-12 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-04-11 10:05 by etl_backfill • Backfilled from existing medication fields
  • side_effects updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • contraindications updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields
  • usage updated 2026-02-12 22:44 by etl_backfill • Backfilled from existing medication fields

FDA Products & Applications (Animal Drugs @ FDA)

Official sponsor/proprietary-name/application-status records linked by active ingredient.

Product Sponsor Application Status Published
Percorten™-V
RX
Desoxycorticosterone Pivalate
Liquid (Suspension) Intramuscular
Elanco US Inc. NADA 141-029 Approved Jun 18, 2018
Zycortal® Suspension
RX
Desoxycorticosterone Pivalate
Injectable Suspension Subcutaneous
Dechra, Ltd. NADA 141-444 Approved Jun 1, 2016

Data source: FDA Animal Drugs @ FDA (public search export).

What It's For (FDA Label Highlights)

Extracted from FDA Animal Drugs @ FDA product labeling. Always confirm details with your veterinarian.

Species: Dog
Composition / specifications
Each milliliter of sterile aqueous suspension contains 25 milligrams of desoxycorticosterone pivalate.
Dogs
Indication
For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency.
Dosage
Dosage requirements are variable and must be individualized on the basis of the response of the patient to therapy. Initial dose of 1 milligram per pound (0.45 kilogram) of body weight every 25 days, intramuscularly. Usual dose is 0.75 to 1.0 milligram per pound of body weight every 21 to 30 days.
Limitations
For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Species: Dog
Composition / specifications
25 mg/mL
Dogs
Indication
For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison’s disease).
Dosage
Administer an initial dose of 2.2 mg/kilogram (1 mg/lb) body weight by subcutaneous injection. Subsequent dosages should be individualized according to label instructions based on patient response to therapy.
Limitations
For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

FDA page: Open in Animal Drugs @ FDA

Usage

For use as replacement therapy for the mineralocorticoid deficit in dogs with primary adrenocortical insufficiency. For use as replacement therapy for mineralocorticoid deficiency in dogs with primary hypoadrenocorticism (Addison’s disease).

Source: FDA Animal Drugs @ FDA • Reference

Contraindications

For intramuscular use only. Do not use in pregnant dogs, dogs suffering from congestive heart disease, severe renal disease, or edema. Federal law restricts this drug to use by or on the order of a licensed veterinarian. For subcutaneous use in dogs only. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Top Reported Reactions (openFDA)

De-duplicated reaction terms grouped by body system from FDA openFDA reports (not verified; does not prove causation).

Digestive
Loss of appetite (1) • Cat Decreased appetite (1) • Cat

Showing top 5 for Digestive.

Skin & allergy
Itching (1) • Dog

Showing top 5 for Skin & allergy.

Neurologic
Unsteady walking (1) • Dog

Showing top 5 for Neurologic.

Effectiveness
Lack of efficacy - NOS (1) • Cat Lack of efficacy (endoparasite) - whipworm (1) • Dog

Showing top 5 for Effectiveness.

Other
Lymphopenia (1) • Cat Localised oedema (1) • Dog Leucocytosis NOS (1) • Dog Laboured breathing (1) • Dog Increased red blood cell count (1) • Cat
Show more (21)
Increased packed cell volume (1) • Cat Hyposensitivity to pain (1) • Dog Hyponatremia (1) • Cat Hypoglycaemia (1) • Cat Hypochloraemia (1) • Dog Hyperkalaemia (1) • Cat Hyperglycaemia (1) • Cat Hyperalbuminaemia (1) • Cat Hyperactivity (1) • Dog High sodium-potassium ratio (1) • Dog Gastrointestinal foreign body NOS (1) • Cat Fever (1) • Dog Falling (1) • Cat Dry mucous membrane (1) • Dog Drunken gait (1) • Dog Drug administration error (1) • Cat Disorientation (1) • Cat Dehydration (1) • Cat Coprophagia (1) • Dog Addison's disease (1) • Dog Abnormal ultrasound finding (1) • Cat

Showing top 5 for Other.

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Adverse Event Case Summaries (openFDA)

These are individual FDA adverse event reports. They are unverified and do not prove the medication caused the reaction.

Dog, Shepherd Dog - Australian, Male, 15 year, 6.804 kilogram • Drug: MSK, Unassigned, Unknown • Reactions: Unsteady walking (ataxia), Unable to walk, Pale mucous membrane, Dry mucous membrane, Laboured breathing… • Outcome: Ongoing

  • Report ID: USA-USFDACVM-2025-US-064279
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Male
  • Age: 15.00 Year
  • Weight: 6.804 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
  • Form: Unassigned
Reactions Reported:
Unsteady walking (ataxia) Unable to walk Pale mucous membrane Dry mucous membrane Laboured breathing Pericardial effusion Leucocytosis NOS
Outcomes: Ongoing

Dog, ['Chihuahua', 'Dog (unknown)'], Female, 13 year, 10.45 kilogram • Drug: MSK, Unknown • Reactions: Weight gain, Polyuria, Polydipsia, High sodium-potassium ratio, Localised oedema • Outcome: Outcome Unknown

  • Report ID: USA-USFDACVM-2025-US-065692
  • Serious AE: Yes
  • Treated For AE: Yes
  • Sex: Female
  • Age: 13.00 Year
  • Weight: 10.450 Kilogram
  • Case-reported brand: MSK
  • Case-reported manufacturer: MSK
  • Route: Unknown
Reactions Reported:
Weight gain Polyuria Polydipsia High sodium-potassium ratio Localised oedema
Outcomes: Outcome Unknown

Data source: FDA openFDA Animal & Veterinary adverse event reports.

Overdose Information

No approved overdose-management text is linked yet. If overdose is suspected, contact a veterinarian or emergency clinic immediately.

Storage & Handling

No approved storage guidance is linked yet for this ingredient. Use manufacturer packaging and veterinary guidance for handling/storage.

Share Your Thoughts

Let others know your experience or advice regarding this medication.

This medication has not been reviewed by a veterinarian yet.